Table 3.
Prognostic value of pathway activity scores and SRD5A1 expression.
| Pathway | Median PFS in Weeks (95% CI) | ||
|---|---|---|---|
| Below Median Score | Above Median Score | Difference 1 | |
| AR | 23 (19–28) | 36 (24–47) | p = 0.035 |
| Notch | 24 (19–28) | 31 (19–43) | p = 0.035 |
| MAPK | 30 (20–40) | 23 (13–33) | p = 0.41 |
| TGFβ | 30 (20–41) | 23 (17–30) | p = 0.40 |
| ER | 24 (22–26) | 35 (27–43) | p = 0.039 |
| HH | 30 (18–42) | 24 (18.0–30) | p = 0.007 |
| PI3K 2 | 29 (23–35) | 24 (16–32) | p = 0.995 |
| SRD5A1 | 18 (5–31) | 38 (34–42) | p = 0.003 |
| Below ROC cut-off | Above ROC cut-off | ||
| AR | 12 (11–13) | 31 (24–38) | p < 0.001 |
| Notch | 18 (10–25) | 31 (24–39) | p = 0.003 |
| SRD5A1 | 21 (13–29) | 47 (32–62) | p = 0.002 |
| Median OS in weeks [95% CI] | |||
| Below median score | Above median score | ||
| AR | 107 (66–147) | 122 (81–163) | p = 0.57 |
| Notch | 122 (93–151) | 112 (15–209) | p = 0.84 |
| MAPK | 112 (85–139) | 126 (76–175) | p = 0.74 |
| TGFβ | 122 (72–172) | 112 (71–154) | p = 0.27 |
| ER | 126 (87–165) | 112 (75–149) | p = 0.59 |
| HH | 154 (68–241) | 107 (83–130) | p = 0.16 |
| PI3K 2 | 121 (76–167) | 105 (93–117) | p = 0.73 |
| SRD5A1 | 97 (83–111) | 168 (99–237) | p = 0.11 |
| Below ROC cut-off | Above ROC cut-off | ||
| AR | 154 (39–270) | 112 (82–143) | p = 0.87 |
| Notch | 126 (85–166) | 107 (79–135) | p = 0.87 |
| SRD5A1 | 97 (82–111) | 175 (96–254) | p = 0.04 |
1 Log-rank test. 2 PI3K, as the inverse of Forkhead Box-O (FOXO) signaling, in the absence of oxidative stress.